Medlab Clinical Valuation

Is MDCDA undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

1/6

Valuation Score 1/6

Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of MDCDA when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate MDCDA's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate MDCDA's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for MDCDA?

Other financial metrics that can be useful for relative valuation.

The above table shows the n/a ratio for MDCDA. This is calculated by dividing MDCDA's market cap by their current preferred multiple.
What is MDCDA's n/a Ratio?
n/a	0x
n/a	n/a
Market Cap	AU$25.12m

MDCDA key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	3.3x
Enterprise Value/EBITDA	-1.3x
PEG Ratio	n/a

Price to Sales Ratio vs Peers

How does MDCDA's PS Ratio compare to its peers?

The above table shows the PS ratio for MDCDA vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PS	Estimated Growth	Market Cap
Peer Average	8.2x
NOX Noxopharm	12.8x	n/a	AU$30.7m
ATH Alterity Therapeutics	5.3x	25.0%	AU$21.3m
BIT Biotron	10.4x	n/a	AU$17.1m
PAB Patrys	4.4x	n/a	AU$6.2m
MDCDA Medlab Clinical	5.6x	27.4%	AU$25.1m

Price-To-Sales vs Peers: Insufficient data to calculate MDCDA's Price-To-Sales Ratio vs. peers for valuation analysis.

Price to Earnings Ratio vs Industry

How does MDCDA's PE Ratio compare vs other companies in the AU Biotechs Industry?

0 Companies	Price / Earnings	Estimated Growth	Market Cap
Industry Avg.	n/a	15.0%
	n/a	n/a	n/a

Fetching data

0 Companies	Price / Earnings	Estimated Growth	Market Cap
Industry Avg.	n/a	15.0%
	n/a	n/a	n/a

No more companies

Price-To-Sales vs Industry: MDCDA is good value based on its Price-To-Sales Ratio (5.6x) compared to the Australian Biotechs industry average (10x).

Price to Sales Ratio vs Fair Ratio

What is MDCDA's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

MDCDA PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio	5.6x
Fair PS Ratio	n/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate MDCDA's Price-To-Sales Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.